Compare LBTYA & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBTYA | IRTC |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | Bermuda | United States |
| Employees | 6636 | N/A |
| Industry | Cable & Other Pay Television Services | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | N/A | 2016 |
| Metric | LBTYA | IRTC |
|---|---|---|
| Price | $11.30 | $103.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | $13.72 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 1.6M | 472.6K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $747,138,000.00 |
| Revenue This Year | $15.41 | $19.60 |
| Revenue Next Year | $3.03 | $15.94 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $9.62 | $100.85 |
| 52 Week High | $13.52 | $210.01 |
| Indicator | LBTYA | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 39.00 | 37.93 |
| Support Level | $10.54 | $101.75 |
| Resistance Level | $11.53 | $121.88 |
| Average True Range (ATR) | 0.40 | 5.30 |
| MACD | -0.06 | -0.38 |
| Stochastic Oscillator | 0.40 | 15.11 |
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.